Biocon Biologics gets DCGI nod for use of CytoSorb in critical COVID-19 cases

Published On 2020-05-28 08:43 GMT | Update On 2020-05-28 08:43 GMT

Biopharmaceutical company Biocon on Wednesday announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India's (DCGI) approval for CytoSorb, an extracorporeal blood purification (EBP) device.

CytoSorb is aimed at reducing pro-inflammatory cytokines levels in critical COVID-19 patients who are being treated in the intensive care unit (ICU) with confirmed or imminent respiratory failure.

The license will be effective until COVID-19 is controlled in the country and will be used for emergency use of CytoSorb to treat COVID-19 patients who are 18 or above.

"As a science-led organization, Biocon's endeavour is to provide innovative solutions to patients to address their unmet needs. CytoSorb is an in-licensed unique device that reduces cytokine storm in critically ill patients and was introduced by Biocon in India in 2013," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

"DCGI approval for emergency use of CytoSorb for critical COVID-19 patients is an important example of how industry and regulators are working in tandem to urgently provide physicians and patients with new treatment options in the fight against COVID-19. CytoSorb will be an important addition to the Indian medical community's arsenal against the deadly coronavirus," she added.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Biocon Biologics gets DCGI nod for use of CytoSorb in critical COVID-19 cases

Similar News

GPAT 2025 Results OUT, Scorecards Available from July 4

Who were the 30 doctors? RTI sparks questions over secrecy in Pharma Freebies case

Sun Pharma Sets Record with Over 1 Lakh Uric Acid Screenings in 3 Days

NBE Releases GPAT 2025 Provisional Answer Keys, Recorded Responses

SC Slams Pharmacy Council of India over Arbitrary Rejection of Approvals to Pharma Colleges

NBE GPAT 2025 Admit Card OUT, Download now

NMC Yet To Take Action Against 30 Doctors Named in Rs 1.91 Cr Freebie Case- RTI Response

No prescription by company brand names: SC calls for statutory mandate for doctors to prescribe generic